Idorsia rolls out insomnia med Quviviq with sales team, digital marketing and DTC in the works – Endpoints News

Lead Marketing & Automation Services > Blog > Uncategorized > Idorsia rolls out insomnia med Quviviq with sales team, digital marketing and DTC in the works – Endpoints News

Idorsia hit the marketing ground running with its insomnia launch, debuting an awareness campaign starring popular “Friends” actress Jennifer Aniston just days after its Quviviq approval in January. Now the insomnia brand hit shelves this week with a sales force rollout to physicians, digital and social media ads and plans for a direct-to-consumer campaign coming soon.
A field team of about 500 sales reps plus another 100 customer-facing medical affairs, market access and others are reaching out to physicians in the first wave of Quviviq marketing, said Patricia Torr, president and general manager of Idorsia US. About 75% of the target group of doctors are primary care, with psychiatry and a few other specialties making up the rest.
Unlock this story instantly and join 141,800+ biopharma pros reading Endpoints daily — and it’s free.
How are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy discusses key fundamentals, macro-awareness and the continued impact of COVID with HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia.
Biotech indexes may be down, but both Snedeker and Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds, see opportunities in the market. In Snedeker’s opinion, investors need to seek out companies with the potential for meaningful revenue growth, particularly those that are mispriced in the current bear market.
Roche has racked up its second straight Phase III fail for its TIGIT tiragolumab, flagging a flop on the progression-free survival co-primary endpoint for the drug combined with Tecentriq as a first-line treatment for PD-L1 high patients suffering from non-small cell lung cancer.
The other co-primary endpoint in the SKYSCRAPER-01 study on overall survival hasn’t reached the readout phase yet. But this time around Roche execs are waiting to see if it just might hit positive after seeing numerical gains for both endpoints.
Unlock this story instantly and join 141,800+ biopharma pros reading Endpoints daily — and it’s free.
GlaxoSmithKline is teaming up with “Beverly Hills 90210” star Jennie Garth around its anti-inflammatory med Voltaren.
Garth, who has osteoarthritis and uses the over-the-counter gel Voltaren, is also a caregiver. She’s partnering with GSK to launch the CareWalks video series where she hosts a walk and talk with other caregivers to discuss their experiences and challenges – and their joint pain.
Unlock this story instantly and join 141,800+ biopharma pros reading Endpoints daily — and it’s free.
Bristol Myers Squibb continues to tout more data for its experimental psoriasis drug that it hopes will shake up the market.
The pharmaceutical giant posted two-year results from a long-term extension study of deucravacitinib, showing the drug remained effective after two years. The drug, which analysts predict can bring in billions in sales by 2026, is an oral TYK2 inhibitor for adult patients with moderate to severe plaque psoriasis.
BridgeBio has located the bridge to greener pastures, specifically the lavish purple of Bristol Myers Squibb.
The two are collaborating in a deal giving the reorganized biotech an upfront payment of $90 million, a capital infusion that comes a week after the Palo Alto, CA biotech disclosed $23 to $25 million in restructuring-related costs. That move also included the out-licensing of six programs, a round of layoffs, consolidation of facilities and other activities in a major re-route.
Awkward side hugs and riding in the back of the “dad cab” are typical adolescent rites of passage. But it’s also around the same time that parents overseeing the pre-teen years should be thinking about HPV vaccinations for their kids.
Merck’s latest HPV vaccine awareness campaign showcases those parent-tween moments in a new TV commercial. The message is delivered by a mom who says, as she gets a surprise full-on hug, “Embrace this phase, help protect them in the next. Ask their doctor about HPV vaccination today.”
Unlock this story instantly and join 141,800+ biopharma pros reading Endpoints daily — and it’s free.
Lupus isn’t fair — and AstraZeneca’s debut direct-to-consumer ad campaign for Saphnelo wants to let patients know that it understands. And that it’s here to disrupt the status quo.
Saphnelo, approved in August, is the first new med for systemic lupus erythematosus (SLE) in more than 10 years. Its type I interferon differs from its lupus market-established competitor GlaxoSmithKline’s Benlysta, a B-cell activating factor inhibitor first approved in 2011.
Unlock this story instantly and join 141,800+ biopharma pros reading Endpoints daily — and it’s free.
The bear market struck again Thursday morning as a New Jersey-based antifungal biotech reported a significant shift in operations.
CorMedix will be shaking up much of its C-suite and halting operations in Europe, the company announced, as it looks to rebound from a March 2021 CRL. The company had re-filed its application about six weeks ago but the changes highlight the new direction as it prepares to meet the FDA once again.
New information has emerged detailing the events that led to the April 23 arrest of Seagen CEO Clay Siegall and a May 2 temporary restraining order against him, according to documents obtained by Endpoints News.
Around 3 a.m. local time on April 23, Siegall’s wife and a witness called police after he allegedly pushed her to the ground, and he was brought to jail hours later on a charge of fourth degree domestic violence gross misdemeanor, per police records from that morning. The records, as well as a restraining order and jail call logs, lay out the allegations against one of the highest-profile CEOs in biotech, who founded Seagen in the late 1990s and has built it into a $22 billion drug developer that led the ADC R&D field. Siegall was also one of the most richly compensated pharma executives in 2021, pulling in $18.1 million.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWS Daily at 11:30 AM ET
EARLY EDITION Daily at 7:15 AM ET
ENDPOINTS PHARMA Daily at 2 PM ET
ENDPOINTS MARKETING RX Tue at 2 PM ET
ENDPOINTS FDA+ Wed at 2 PM ET
ENDPOINTS MANUFACTURING Thu at 2 PM ET
ENDPOINTS WEEKLY Sat at 6 AM ET

source